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ABSTRACT
Allogeneic hematopoietic cell transplantation (HCT) has been shown to be curative in a group of patients with
aggressive non-Hodgkin lymphoma (NHL). A previous study has demonstrated equivalent outcomes with a
conditioning regimen based on total body irradiation and another not based on total body irradiation with
preparative therapy using cyclophosphamide, carmustine, and etoposide (CBV) in autologous HCT. We
investigated the safety and efficacy of using CBV in an allogeneic setting. Patients were required to have
relapsed or be at high risk for subsequent relapse of NHL. All patients had a fully HLA-matched sibling
donor. Patients received carmustine (15 mg/kg), etoposide (60 mg/kg), and cyclophosphamide (100 mg/kg)
on days 6, 4, and2, respectively, followed by allogeneic HCT. All patients were treated with cyclosporine
and methylprednisolone as prophylaxis for graft-versus-host disease (GVHD). Thirty-one patients (median
age, 46 years) who were felt to be inappropriate candidates for autologous transplantation were enrolled. Each
subject had a median of 3 previous chemotherapy regimens. All patients engrafted. Fifteen of 31 patients are
alive. Median follow-up time was 11.5 months (range, .4-126). There were 8 deaths due to relapse. Nonrelapse
mortality (n  8) included infection (n  3), GVHD (n  2), diffuse alveolar hemorrhage (n  1), veno-
occlusive disease in the setting of concurrent acute GVHD of the liver (n  1), and leukoencephalopathy (n 
1). Probabilities of event-free survival and overall survival were, respectively, 44% (95% confidence interval,
26%-62%) and 51% (33%-69%) at 1 year and 44% (26%-62%) and 47% (29%-65%) at 5 years. Probability of
relapse was 33% (15%-51%) at 1 year and 5 years. Probability of nonrelapse mortality was 31% (13%-49%) at
1 year and 5 years. Incidences were 29% for acute GVHD and 39% for chronic GVHD. None of the 12 patients
who developed chronic GVHD has disease recurrence. Patients who had required >3 previous chemotherapy
regimens before HCT had an increased probability of relapse. CBV is an effective preparative regimen for
patients with aggressive NHL who undergo allogeneic HCT.
© 2006 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Non-Hodgkin lymphoma (NHL) is a malignant
isease with increasing incidence [1]. With conven-
ional chemotherapy, 40% to 50% of patients may be
ured [2]; however, many patients relapse after initial themotherapy. For those who relapse, high-dose che-
otherapy followed by autologous hematopoietic cell
ransplantation (HCT) has been shown to improve
urvival [3]. Despite such treatment, relapse remains
he major cause of failure. Several potential reasons
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L. Y. Law et al.704or relapse can be identiﬁed. One possibility is that the
ematopoietic cells that have been collected may con-
ain clonogenic tumor cells, which could be reinfused
uring the HCT procedure. Two studies using sensi-
ive molecular assays have found that the bone marrow
s frequently contaminated with malignant cells in
ow- and intermediate-grade lymphomas [4,5].
High-dose chemotherapy with allogeneic HCT
as been used extensively for myeloid and lymphoid
eukemias with signiﬁcant improvement in survival
ompared with standard chemotherapy [6-9]. The use
f allogeneic HCT has been investigated in patients
ith refractory NHL and achieved results superior to
hat expected with standard chemotherapy regimens
10-12]. Its efﬁcacy has been attributed to a graft-
ersus-lymphoma (GVL) effect and possibly to a graft
hat is free of tumor cells [13]. Various preparative
egimens have been used in the allogeneic setting,
ith most being based on total body irradiation (TBI).
e previously reported a study that demonstrated
cceptable toxicity and survival equivalent to a non-
BI preparatory regimen of cyclophosphamide, car-
ustine (BCNU), and etoposide (VP-16; CBV) for
atients with NHL who received autografts compared
ith a TBI-based regimen. This regimen has an out-
ome equivalent to those containing TBI with less
oxicity [14]. In addition, we previously described our
xperience with allogeneic HCT using a regimen of
BI, VP-16, and cyclophosphamide for patients with
dvanced or refractory leukemias and lymphomas
15,16]. Because of the decreased toxicity of CBV
ompared with a TBI-based regimen and equivalent
isease control in autografting, this study investigated
he safety, toxicity, efﬁcacy, and tolerability of this
ame regimen (CBV) in an allogeneic setting using
yclosporine (CSP) and methylprednisolone (PSE) as
rophylaxis for graft-versus-host disease (GVHD) in
atients who had relapsed or were at high risk for
ubsequent relapse of NHL.
ATERIALS AND METHODS
atient Eligibility
Between February 1992 and March 2004, 31 adult
atients with relapsed NHL or a high risk for subse-
uent relapse of NHL with fully HLA-matched re-
ated donors received allogeneic HCT at Stanford
niversity (Stanford, Calif). The ﬁrst 4 patients re-
eived bone marrow grafts. The subsequent 27 pa-
ients received granulocyte colony-stimulating factor
G-CSF), mobilized, allogeneic peripheral blood he-
atopoietic cells. No graft was manipulated.
Eligible patients were 18 to 60 years old with
orphologically conﬁrmed NHL. Exclusion criteria
ere (1) hepatic dysfunction that was deﬁned by a
erum transaminase level2.5 times the normal value, o2) serum creatinine level 2 mg/dL or creatinine
learance 60 mL/min, (3) previous bone marrow
ransplantation procedure, (4) major organ dysfunc-
ion that might increase the risk of the transplantation
rocedure, or (5) severe psychological or medical ill-
ess. All patients and donors gave written informed
onsent as required by the institutional review board
f Stanford University.
tudy Definitions
Patients without clinical or radiologic evidence of
isease or bone marrow involvement with lymphoma
ere deﬁned as being in complete remission (CR), and
atients with measurable residual disease were deﬁned
s being in partial remission (PR). Patients who did
ot respond to standard chemotherapy at initial pre-
entation were classiﬁed as having induction failure
IF). Relapse was deﬁned by evidence of radiographic
r clinical progression in a new site or growth of
isease in any previously involved sites.
Patients were considered to have bone marrow
nvolvement if they had NHL demonstrated in the
one marrow at any time before allogeneic HCT.
onrelapse mortality (NRM) included death from
ny cause except relapse. The day of allogeneic HCT
as deﬁned as day 0 for all survival and relapse anal-
ses. Event-free survival (EFS) was calculated by scor-
ng relapse or death from any cause as an event.
atient Characteristics
Patient characteristics are listed in Table 1. Thirty-
ne patients were treated in this study. Of these, 21
ere men and 10 were women, with a median age of
6 years. Histologic classiﬁcation was based on the
orking Formulation, which was the principal clas-
iﬁcation system in use during the period under study
17]. Patients were categorized into 4 groups accord-
ng to histologic NHL subtype: low grade (n  2),
ntermediate grade (n  21), high grade (n  3), and
ransformed (n 5). Most patients had stage 4 disease
t the time of transplantation (n  24). Thirty-nine
ercent (12 of 31) of patients had bone marrow in-
olvement and 58% (18 of 31) had extranodal disease.
mong the 31 patients, 8 were in CR (3 in ﬁrst CR
nd 5 in the second or subsequent CR), 15 were in PR,
nd 8 had IF. For those who had chemosensitive
isease (CR and PR) at the time of transplant (n 23),
large proportion had 1 relapse previously, with 5,
, and 2 patients in their second, third, and fourth
ecurrences, respectively. Most patients were heavily
retreated before HCT, with 10 having had3 previous
egimens. Thirteen of the 31 patients had previous ra-
iation, and 3 received radiation to the mediastinal area.
mong the 21 patients with intermediate-grade histol-
gy, 5 had IFs and 5 had short disease-free intervals,
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CBV and Allogeneic HCT in Patients with NHL 705ith the time from ﬁrst remission to ﬁrst relapse being
6 months (range, 1-5).
ollection of Allogeneic Hematopoietic Cells
Patients were required to have a fully HLA-
atched sibling donor. HLA compatibility was deter-
ined by serologic methods for HLA class I antigens
nd at least low-resolution molecular typing for HLA
able 1. Patient and Donor Characteristics
atients, n 31
ge, y
Median 46
Range 20-60
ender
Male 21
Female 10
istology
High grade
Burkitt 2
T-cell lymphoblastic lymphoma 1
Intermediate
Diffuse large B-cell cell 10
Mantle cell 5
NK T-Cell 1
T-cell rich B cell 2
Mixed histology 3
Low grade
Follicular small cleaved 1
Marginal zone 1
Transformed 5
tage at time of transplantation
2 1
3 6
4 24
one marrow involvement 12
xtranodal involvement 18
symptoms 14
isease status at time of transplant
First CR 3
Second or subsequent CR 5
First PR 4
Second or subsequent greater PR 11
IF 8
o. of relapses (first CR, first PR, and IF excluded)
1 6
2 5
3 3
4 2
rior chemotherapy regimens
>3 10
<3 21
rior radiation 13
rior mediastinal radiation 13
onor age, y
Median 45
Range 17-64
onor gender
Male 21
Female 10
atient-donor pair sex mismatched 16
atient-donor pair CMV-seronegative 6lass II antigens. Bone marrow harvest was performed tnder anesthesia for the ﬁrst 4 patients [18]. Begin-
ing in July 1999, patients received G-CSF, “mobi-
ized,” allogeneic hematopoietic cells. HLA-matched
onors received G-CSF at a dose of 16 g/kg/d sub-
utaneously beginning on day 5. On day 1, the
rst apheresis collection began in the afternoon for a
- to 4-hour apheresis procedure. The goal was 5 
06 CD34 cells/kg of recipient weight. If this goal
as not achieved in the ﬁrst apheresis procedure, a
econd apheresis was performed on the morning of
ay 0. A minimum dose of 2  106 CD34 cells/kg of
ecipient weight was required for the allografting pro-
edure. The hematopoietic cell products were not
anipulated.
reparative Regimen
The preparative regimen consisted of BCNU 15
g/kg (maximum dose, 550 mg/m2 actual body weight)
n day 6 infused over 2 hours, etoposide 60 mg/kg on
ay4 infused over 4 hours, and cyclophosphamide 100
g/kg infused over 2 hours on day 2 [19]. All chemo-
herapy was based on adjusted ideal body weight.
llogeneic Hematopoietic Cell Infusion
Hematopoietic cells from fully HLA-matched sib-
ings were infused on day 0. Patients were premedi-
ated with diphenhydramine 50 mg intravenously and
ydrocortisone 100 mg intravenously before hemato-
oietic cell infusion. Fresh hematopoietic donor cells
ere administered from 30 minutes to 3 hours, de-
ending on total volume.
mmunosuppression
Post-transplant immunosuppression was achieved
y using intravenous CSP and PSE [20]. Intravenous
SP 3 mg/kg/d was given over 24 hours beginning on
ay 1. For patients who received bone marrow
rafts, PSE was administered at .25 mg/kg 2 times a
ay beginning on day 7 and increased to .5 mg/kg 2
imes a day on day 14. For patients who received
llogeneic hematopoietic cells, intravenous PSE was
dministered at .5 mg/kg 2 times a day on day 7
hrough day 28. Beginning on day 29, all patients’
SE dose was decreased to .4 mg/kg 2 times a day,
nless they were being treated for GVHD. Adjust-
ent of CSP was based on serum, creatinine, and total
ilirubin levels.
upportive Care and Follow-up
All patients were housed in private rooms with
igh-efﬁciency particulate air ﬁltration systems. Gut
econtamination was attempted with nonabsorbable
ral antibiotics or ciproﬂoxacin. Pneumocystis carinii (P.
iroveci) prophylaxis was instituted at the beginning of
he preparatory regimen with trimethoprim/sulfame-
hoxazole for 4 days and reinstituted on day 42 through
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L. Y. Law et al.706iscontinuation of immunosuppressive drugs. Patients
eceived prophylactic acyclovir 5 mg/kg if the patient
ested positive for herpes simplex virus beginning on day
1 and was discontinued when mucositis resolved. An-
ifungal therapy with ﬂuconazole 400 mg was given on
ays1 through75. Vancomycin and broad-spectrum
ntibiotics were started when the patient developed fe-
rile neutropenia. Growth factors were not routinely
dministered. Weekly quantitative cytomegalovirus
CMV) polymerase chain reaction (PCR) surveillance
as done on days 21 through 100. Initiation of
ihydroxyphenylglycol (ganciclovir) commenced with
single positive PCR of peripheral blood. Intravenous
mmunoglobulin 500 mg/kg was administered
onthly from day1 until day100. All blood prod-
cts were radiated with 2500 cGy and CMV-negative
lood products were used for patients who were sero-
egative for CMV. Platelets were transfused to main-
ain a platelet count 10 000/L, and red blood cells
ere transfused to maintain a hematocrit value30%.
efore November 2002, patients received low-dose
eparin 100 U/kg/d by continuous infusion for pre-
ention of hepatic veno-occlusive disease (VOD) and
ontinued until white blood cell engraftment was de-
ected. Subsequent to that date, patients received ur-
odeoxycholic 6 mg/kg/d as hepatic VOD prophylaxis
ntil day 90.
Tumor staging using computed tomograms were
erformed at 3, 6, and 12 months after HCT and
nnually thereafter. Bone marrow biopsies were ob-
ained routinely to assess engraftment and examined
or lymphoma and donor chimerism on days 60, 100,
80, and 365 and at years 2, 3, 5, 7, and 10. A physician
ubsequently examined patients every 2 to 6 months,
ith chest radiographs performed at each visit and
dditional radiographic studies ordered as indicated.
ocumentation of Hematopoietic Engraftment
The time required for white blood cell engraft-
ent was deﬁned by the ﬁrst day on which the abso-
ute granulocyte count reached .5  109/L. Platelet
ngraftment was deﬁned as unsupported platelet
ounts 25  109/L. Engraftment of donor cells was
lso documented by cytogenetic analyses of recipient
arrow cells after transplantation and ampliﬁcation of
ighly variable DNA regions (short tandem repeats)
f different sex-independent genes by PCR.
efinitions of Toxicity and Response
Early regimen-related toxicity was evaluated ac-
ording to established transplantation-speciﬁc criteria
21]. Acute GVHD (aGVHD) and chronic GVHD
cGVHD) were graded according to consensus crite-
ia [22]. Biopsies were obtained whenever required to
onﬁrm the diagnosis. Statistical Methods
The ﬁnal follow-up was completed on November
2, 2004, and EFS and overall survival (OS) were
stimated with the method of Kaplan and Meier [23]
nd calculated as the day of bone marrow or periph-
ral blood hematopoietic cells infusion until the date
f ﬁnal follow-up examination. The relationships be-
ween clinical parameters and survival were evaluated
sing Cox univariate analysis.
ESULTS
ematologic Reconstitution
All 31 patients engrafted.Median time to recovery of
n absolute neutrophil count .5  109/L was 11 days
range, 8-16). Similarly, median time to platelet recovery
25  109/L independent of transfusion in 30 patients
ho could be evaluated was 16 days (range, 13-27).
edian number of days of hospitalization was 23
range, 18-38).
linical Outcome
Outcomes for the 31 patients are listed in Tables
to 4. Twenty-one of 31 patients attained CR after
CT at their ﬁrst evaluation, including 6 who had IFs
nd 8 who were in PR at the time of transplantation;
were in CR at time of transplantation and main-
ained at CR after HCT. As of November 2004, 15
48%) were alive and 14 (45%) were without disease at
edian follow-ups of 11.5 months (.4-126) for all
atients and 25.2 months (7.2-126) among the 15
urviving patients. Sixteen patients died. Fifty per-
ent of deaths (n  8) were due to relapse. The
ther causes of death included infectious complica-
ions (n  3), GVHD (n  2), organ toxicities (n 
), and GVHD in combination with organ toxicity
ue to VOD (n  1). Regimen-related toxicities
ncluded diffuse alveolar hemorrhage (n  1), VOD
n  1), and leukoencephalopathy (n  1). Five
atients died 100 days after transplantation, 10
able 2. Clinical Outcome After Allogeneic HCT in NHL
y Disease Status
Disease Status Before
Transplantation
Disease Status After
Transplantation at First
Radiographic
Evaluation
No. of
Patients
IF CR 6
PR CR 8
CR CR 7
PR PR 1
PR SD 1
PR PD 5
IF PD 2
CR PD 1D indicates stable disease; PD, progressive disease.
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CBV and Allogeneic HCT in Patients with NHL 707ied between day 100 and 1 year after transplan-
ation, and 1 died 1 year after HCT. The most
ommon cause of death at 100 days was organ
oxicity (n  3) and the most common cause of
eath in the ﬁrst year after transplantation was re-
apse (n  7).
raft-versus-Host Disease
The actuarial incidence of grade II-IV aGVHD
as 29% (2 with grade II, 3 with grade III, and 4 with
rade IV). Four patients had gastrointestinal tract
VHD, 3 had involvement of the gastrointestinal
ract and the skin, and 2 had liver GVHD. All patients
ere given CSP and steroids as GVHD prophylaxis
nd all cases of aGVHD developed while patients
ere on CSP. Patients who developed aGVHD re-
eived further immunosuppressive therapy. Two died
f infectious complications. Both patients with liver
VHD died, 1 in the setting of a hepatitis C ﬂare and
in the setting of concurrent VOD. One patient
ubsequently progressed to cGVHD of the lung and
ventually died. The remaining 4 responded to treat-
ent.
Twelve patients developed cGVHD (39%); aGVHD
n 3 patients progressed to cGVHD and 9 developed de
ovo cGVHD. Among the 3 with progressive cGVHD,
had lung involvement and eventually died, 1 had
xtensive disease and is alive on active treatment, and
had limited disease and responded to local therapy.
mong the 9 patients who developed de novo
GVHD, only 1 had extensive disease. The remaining
atients (n  8) had limited involvement. Sites that
ere involved among these 8 patients included the
kin, eyes, mucosa, and pancreas.
urvival Analysis
Probabilities of OS estimated at 1 year and 5 years
fter allogeneic HCT as determined by the Kaplan-
eier method were 51% (95% conﬁdence interval,
able 3. Clinical Outcome by Subgroup Analysis
No. of
Patients
No. of
Relapses
Years to Relapse,
Median (range)
istology
Low grade 2 0 —
Intermediate grade 21 6 .23 (.02-.34)
High grade 3 0 —
Transformed 5 3 .38 (.19-.48)
isease status before
transplantation
CR 8 2 .32 (.26-.38)
PR 15 5 .29 (.02-.48)
IF 8 2 .18 (.16-.19)
hemosensitivity to final
treatment
Chemosensitive 23 7 .29 (.02-.48)s
Chemoresistant 8 2 .18 (.16-.19)3%-69%) and 47% (29%-65%), respectively. The
robability of EFS estimated at 1 year and 5 years was
4% (26%-62%; Figure 1, OS and EFS curves). A
lateau in EFS was observed 1 year after HCT.
Among the 8 patients who relapsed and died, all
ad relapsed within the ﬁrst 6 months after HCT.
even died within the ﬁrst year after transplantation
nd 1 died 1 year after transplantation. There were no
ate relapses. Among these 8 patients with early re-
apse, 3 had transformed NHL and 5 had heavily
retreated intermediate-grade NHL, with a median of
previous chemotherapy regimens before HCT.
There were 8 deaths due to nonrelapse causes: 3
rom infection, 2 from GVHD, 1 from diffuse alveolar
emorrhage, 1 from VOD in the setting of concurrent
iver aGVHD, and 1 from leukoencephalopathy.
robabilities of relapse and NRM were 33% (15%-
1%) and 31% (13%-49%), respectively, at 1 year and
years (Figure 2, relapse and NRM curves).
Univariate analysis showed that patients who re-
eived 3 previous chemotherapy regimens had an
ncreased probability of relapse (P  .004; relative
isk, 10; 95% conﬁdence interval, 2-52). All other
nalyzed clinical parameters (including gender, pa-
ient CMV status, donor CMV status, histology, bone
arrow involvement, extranodal site involvement, B
ymptoms, previous radiation, disease status at trans-
lantation, source of hematopoietic cells, and tumor
hemosensitivity) were not found to be statistically
able 4. Clinical Outcome Based on Survival
Patients, n (%)
live 15 (48)
No evidence of disease 14
Relapse 1
eceased 16 (52)
Relapse mortality 8 (26)
NRM 8 (26)
Infections 3
GVHD* 2
Diffuse alveolar hemorrahge 1
VOD and liver GVHD 1
Leukoencephalopathy 1
Early (<100 d after transplantation) 5 (16)
Infections 1
Toxicity† 3
Relapse 1
Day 100 to 1 y after transplantation) 10 (32)
Infections 2
GVHD 2
Relapse 6
Late (>1 y after transplantation) 1 (3)
Relapse 1
Acute (grade III) in liver (n  1), chronic in lung.
Diffuse alveolar hemorrhage (n  1), VOD with GVHD (n  1),
and leukoencephalopathy (n  1).igniﬁcantly correlated with OS, EFS, or relapse.
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L. Y. Law et al.708ISCUSSION
Autologous HCT is the standard of care for pa-
ients with chemotherapy-sensitive recurrent NHL
3]. However, for those with chemotherapy-resistant/
efractory or high-grade aggressive disease, autolo-
ous HCT rarely produces durable remission. In this
tudy, patients were selected for an allograft because
f their high-risk NHL, with most having been
eavily pretreated or having a short disease-free inter-
al or IF or an autograft was judged to be insufﬁcient
o provide long-term remission and survival.
TBI-based regimens are commonly used as part of
yeloablative preparative regimens in allogeneic bone
arrow transplantation for patients with hematologic
alignancies [15,24,25]. The nonradiation-based con-
itioning regimen with high-dose CBV was ﬁrst re-
orted in 1987 by Zander et al [26] to be successful in
llowing durable engraftment in patients with acute
eukemia who received allogeneic bone marrow trans-
lants. In a comparative analysis, this chemotherapy-
nly preparatory regimen was found to be equivalent
n outcome to TBI-based therapy in autotransplanta-
ion for NHL [14].
Allogeneic HCT for aggressive NHL has been
Figure 1. OS (solid line) and EFS (dashed line) probabilitieFigure 2. Probabilities of NRM (solid line) and relapse (dashed line) fssessed in several single-arm cohort studies. Most of
hese studies had small numbers of patients and com-
rised heterogeneous groups of patients with different
istologies and stages of disease. In addition, there was
variety of preparative regimens, ranging from radi-
tion based [27-29] to nonradiation based [30-34].
oocey et al [29] recently reported similar EFS and
S values of 40%-50% after using a primarily TBI-
ased conditioning regimen in an allogeneic setting,
lthough their patient cohorts were less heavily pre-
reated and had more interstitial pneumonitis than did
hose in our present report. CBV as a preparative
egimen has also been reported by Demirer et al [30]
nd Rossi et al [33], with comparable results. Based on
he results of these studies, it is apparent that a subset
f patients achieve long-term disease-free survival
ith allogeneic HCT despite recurrent, refractory, or
igh-risk disease at the time of transplantation. This
nding suggests the advantage of a tumor-free graft
nd potential GVL effectiveness.
Evidence of a GVL effect has been conﬂicting,
rimarily due to lack of randomized studies [35,36].
ifferent comparative trials have reported improved
utcomes for patients who received an allogeneic
1 patients treated with CBV followed by allogeneic HCT.or 31 patients treated with CBV followed by allogeneic HCT.
H
E
(
w
p
r
d
a
[
m
h
a
i
t
t
o
B
r
t
e
b
v
t
n
t
w
i
c
i
m
c
a
s
t
r
t
p
t
t
s
t
t
f
e
k
r
t
s
b
I
p
i
a
b
r
c
1
C
p
p
a
t
n
N
p
6
d
d
f
t
s
r
e
t
d
o
a
p
ﬁ
t
y
a
a
a
h
a
e
d
p
u
o
m
A
s
t
t
a
t
R
CBV and Allogeneic HCT in Patients with NHL 709CT [12,37]. In a large retrospective analysis by the
uropean Bone Marrow Transplantation Registry
EBMT), allogeneic transplantation was associated
ith a lower relapse rate than was autologous trans-
lantation [37]. Further, lower relapse rates had been
eported in the presence of GVHD [38]. In addition,
isease response to withdrawal of immunosuppression
nd donor lymphocyte infusion has been reported
10,39]. Unfortunately, due to high procedure-related
ortality with allogeneic transplants, the GVL effect
as not been correlated with superior OS despite its
ssociation with a lower relapse rate, as demonstrated
n the EBMT analysis [37]. Conversely, other small
rials have not consistently demonstrated the correla-
ion of decreased relapse rates with allogeneic HCT
ver autologous HCT [40]. A comparative analysis by
ierman et al [41] showed no difference in relapse
ates after syngeneic HCT versus allogeneic HCT. In
he analysis by Dhedin et al [10], there was no inﬂu-
nce of GVHD on relapse.
In the present study, the GVL effect is supported
y the ﬁnding that none of the 12 patients who de-
eloped cGVHD has recurrent disease. For those pa-
ients who relapsed, donor lymphocyte infusion was
ot performed due to rapidly progressive disease, al-
hough it may still have a curative role in patients
hose disease is indolent in nature or when the relapse
s aggressive but enters a minimal disease state after
ytoreductive therapy.
The importance of chemosensitivity in determin-
ng outcome after allogeneic HCT has been shown in
ultiple studies [7,10,12,28,38,42]. In our study, no
orrelation was demonstrated between disease status
nd survival. Eight of the 31 patients in the present
tudy had IF before transplantation. Of these 8 pa-
ients, 6 were converted to CR at the time of their ﬁrst
adiographic evaluation. One possible explanation for
his ﬁnding is the potential effectiveness of our pre-
arative regimen and the presumed GVL effect from
he graft itself. Another explanation is that our pa-
ients were heterogeneous in histology and disease
tatus such that a signiﬁcant difference was not de-
ected. Nevertheless, the initial success of being able
o convert from IF to CR after allogeneic HCT can be
urther improved by post-transplant therapies such as
arly donor lymphocyte infusion, infusion of cyto-
ine-induced killer cells [43], antibodies to CD20, or
adiolabeled antibodies to anti-CD20 to decrease fu-
ure relapse.
Myeloablative allogeneic HCT in NHL still has
ubstantial morbidity and mortality. High NRM has
een reported to be in the range of 20%-50% [10,28].
n the present trial, the NRM was 26%, with 10% of
atients dying of treatment-related organ toxicity. Id-
opathic pneumonitis can be a fatal complication after
llogeneic HCT. For patients who received TBI-
ased therapy, development of idiopathic pneumonitisanged from 9% to 23% [27-29]. For those who re-
eived non-TBI regimens, incidences from 6% to
6% have been reported [30,33]. In our study with
BV, none of our patients (including 3 who had
revious chest radiation) developed documented idio-
athic pneumonitis. This further supports CBV as an
lternative to TBI-based regimens, especially for
hose who previously received mediastinal radiation.
Nonmyeloablative or decreased-intensity alloge-
eic hematopoietic transplants have been studied for
HL. Such preparative regimens result in low trans-
lantation-related mortality and high 2-year OS of
2%-71% [44-50]. Faulkner et al [49] found the ad-
ition of anti-CD52 antibody (alemtuzumab) further
ecreased GVHD without increasing the risk of in-
ection. A nonmyeloablative approach may be an al-
ernative for patients with chemosensitive, low-bulk,
table disease at the time of transplantation.
In the present study, despite the incidences of
elapse and NRM, it is important to note that most
vents occurred within the ﬁrst year of transplanta-
ion. For those 8 patients who relapsed, 7 relapsed and
ied within the ﬁrst year of transplantation. More-
ver, for those who died of nonrelapse causes (n  8),
ll died within the ﬁrst year. This is evident in the
lateau shown in the EFS curve in Figure 1. This
nding suggests that the chance of relapse or other
ransplantation-related mortality is very minimal 1
ear after HCT.
In conclusion, CBV as a preparative regimen for
llogeneic transplantation in combination with CSP
nd PSE as GVHD prophylaxis has acceptable toxicity
nd is an effective therapy in patients with relapsed or
igh-risk NHL. A proportion of these patients
chieve long-term survival despite an aggressive dis-
ase status before HCT. Further, this study further
emonstrates evidence of a durable GVL effect. For
atients with aggressive NHL, myeloablative HCT
sing CBV as conditioning therapy remains a viable
ption. Novel strategies are needed to further mini-
ize regimen-related toxicity, GVHD, and relapse.
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